Haleon (HLN) 17th Annual Global Consumer Staples Conference 2024 summary

Growth strategy and performance

• Achieved 4-6% organic sales growth target for two consecutive years, driven by balanced pricing and volume growth.

• Maintains confidence in 4-6% medium-term growth, reaffirming guidance for the current year.

• Market share gains in 69% of the business, with a focus on resilience and category strength.

• Portfolio benefits from natural hedging, with different categories offsetting each other’s volatility.

• Health and brand loyalty remain key consumer drivers.

Category and brand insights

• Sensodyne continues to have growth runway, with Parodontax showing even greater potential.

• Annual product launches, such as Clinical White, drive innovation and dentist recommendations.

• Clinical White is expanding in 10 markets, with a strong Sensodyne pipeline for the next three years.

• Parodontax and Sensodyne both experiencing strong global consumption and share growth.

• Centrum Silver’s new clinical claims have driven significant growth, especially in the U.S. and China.

Financials and margin outlook

• Operating margin expanded by 50 basis points in H1; on an organic basis, up 160 basis points.

• Margin improvement driven by productivity programs, supply chain optimization, and plant rationalization.

• Maidenhead plant closure and production shift to Slovakia expected to lower costs.

• New supply chain leadership aims to unlock further productivity over the next six years.